Chemo or Not?
Tumor profiling tests that predict the likelihood of distant recurrence can help some women with early-stage, hormone receptor-positive breast cancer decide on treatments after surgery.
Progress Against Cancer
Tumor profiling tests that predict the likelihood of distant recurrence can help some women with early-stage, hormone receptor-positive breast cancer decide on treatments after surgery.
The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients...
Clinical outcomes are similar between Black and non-Black patients when patients receive identical treatment and follow-up in a highly structured study environment, researchers say. When Black patients were included in proportion to the larger...
Women who have been diagnosed with breast cancer are at greater risk for developing high blood pressure and diabetes, common risk factors for heart disease.
Factors associated with the imaging facility, rather than individual characteristics, may explain some of the differences the accuracy of mammograms across racial and ethnic groups.
As outcomes improved for cancer patients in states that expanded Medicaid, disparities in survival disappeared.
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
The FDA approved olaparib for patients with breast cancer who have inherited BRCA mutations and have received prior neoadjuvant or adjuvant immunotherapy The U.S. Food and Drug Administration (FDA) has approved the PARP inhibitor...
Aspirin is ineffective in preventing breast cancer recurrence, and immunotherapy holds promise for some patients with advanced anal cancer.
Results favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now